This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole

This study has been terminated.
(Lack of funding prevented further recruitment)
Sponsor:
Collaborator:
National Alliance for Research on Schizophrenia and Depression
Information provided by (Responsible Party):
Jennifer Keller, Stanford University
ClinicalTrials.gov Identifier:
NCT01066897
First received: February 9, 2010
Last updated: April 11, 2017
Last verified: April 2017
February 9, 2010
April 11, 2017
February 2010
February 2013   (Final data collection date for primary outcome measure)
  • Number of Participants Who Discontinued Study Due to Side-effects of the Medication [ Time Frame: throughout the 8 weeks ]
  • % Change in Hamilton Depression Rating Scale From Baseline to week8 [ Time Frame: Baseline and weeks 8 ]

    Utilized the Hamilton Depression Rating Scale, 21-item version to assess depressive symptoms, with a range of 0-63. Higher scores equals more depression. For the change score, where higher equals greater improvement in depressive symptoms.

    Healthy controls were not utilized in this analysis, as no week 8 ratings for health controls were obtained.

  • Change in Mesolimbic Reward System Activity From Pre to Post Treatment (8 Weeks) [ Time Frame: baseline and Week 8 ]
    Because of the limited number of depressed patients who completed the study (n=5) and noisy/unusable imaging data at various time points, this data was unable to be examined.
  • Intolerable side effects occur [ Time Frame: throughout the 8 weeks ]
  • Hamilton Depression Rating Scale [ Time Frame: 8 weeks: > 50% reduction in score from baseline ]
Complete list of historical versions of study NCT01066897 on ClinicalTrials.gov Archive Site
Mesolimibic Reward Activity Baseline Differences in Depression vs Healthy Controls [ Time Frame: Baseline ]
Because of the small number of depressed patients and noisy/unusable data, analyses were not run.
Not Provided
Not Provided
Not Provided
 
Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
We hope to learn how a brain circuit that is important to the understanding of depression, anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and related symptoms. Adults who have a diagnosis of major depression and are not completely responsive to antidepressant medication will be sought out for participation; as will an equal number of adults not suffering from the disorder. Those suffering from depression will be given pramipexole, an investigational medication for eight weeks during which information will be collected about mood, cognition, and brain function. Adults not suffering from depression will also be evaluated with these measures.

Patients who meet DSM-IV criteria for major depression(using the SCID),have a Hamilton Depression Rating Scale score of at least 18, and who are not complete responders to antidepressant medications will be invited to participate in an open label study with pramipexole. Patients who are not complete responders to an adequate trial of an antidepressant (see inclusion criteria below) will be openly treated with pramipexole for 8 weeks. Participants must be between the ages of 20-55 and will include both men and women. Patient's mood will be assessed each visit using the Hamilton Depression (HDRS) and will also complete a series of questionnaires. This will include the physical and social anhedonia scales (Chapman et al., 1976; Eckblad et al., 1982), the Snaith-Hamilton Pleasure Scale (SHAPS; Franken et al., 2007; Snaith et al., 1995), the Mood and Anxiety Symptom Questionnaire Short Form (MASQ; Watson, Weber, et al., 1995; Watson, Clark, et al., 1995), and the Positive and Negative Affect Scale (Watson & Clark, 1991)among others. No other adjunctive agents will be allowed during the eight weeks of the study. Patients will be seen for four weeks on a weekly basis, then biweekly thereafter.

Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.

Depressed participants will also undergo functional MRI and neuropsychological testing twice, once at baseline and once after completion of the medication. 20 healthy control subjects with no history of Axis I disorders and who score less than 5 on the HDRS will participate in the baseline MRI, neuropsychological testing, and clinical ratings/questionnaires.

Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Depression
Drug: Pramipexole
Patients will received increasing dose of pramipexole
  • Experimental: Pramipexole
    Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
    Intervention: Drug: Pramipexole
  • No Intervention: Healthy Controls
    Non depressed, non-intervention comparison group
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
16
February 2013
February 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Must meet DSM-IV criteria for Major Depressive Disorder
  2. HAM-D score >18 on a 21-item assessment at eligibility
  3. On at least an adequate dose of fluoxetine (40 mg/day), paroxetine (40 mg/day) paroxetine CR (50mg), sertraline (150 mg/day), citalopram (40 mg/day), escitalopram (20 mg/day), venlafaxine (150 mg/day), mirtazapine (30 mg/day), or duloxetine (60 mg/day) for at least 6 weeks (monotherapy).
  4. 20-55 years of age

Exclusion Criteria:

  1. Substance abuse in the past 6 months
  2. ECT in the past 6 months
  3. On a MAOI, tricyclic antidepressant, lithium, an antipsychotic, thyroid augmentation, 2 antidepressants simultaneously or lamotrigine
  4. History of any psychosis including psychotic depression
  5. History of Bipolar I, Bipolar II, or Bipolar NOS illness, or concurrent symptoms of mania or hypomania that do not meet the criteria for any bipolar disorder
  6. History of compulsive gambling
  7. Pregnant females or females of childbearing years not using adequate birth control in the opinion of the investigators
  8. Known sensitivity to Pramipexole
  9. Significant suicide risk in the opinion of the investigators
  10. Significant medical conditions that would preclude safe participation in the study in the opinion of the investigators
  11. Psychoactive drugs other than one of the antidepressants listed on Inclusion criteria #4. (A non-barbiturate sedative or hypnotic or benzodiazepine such as trazodone 50mg/day, zolpidem 10mg/day, lorazepam 3mg/day or clonazepam 2mg/day will be allowed if it has been in use for at least 1 month prior to the baseline visit.)
  12. Significant abnormalities are observed in screening laboratory evaluation.
Sexes Eligible for Study: All
20 Years to 65 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01066897
SU-02042010-4902
17847
No
Not Provided
Not Provided
Not Provided
Jennifer Keller, Stanford University
Stanford University
National Alliance for Research on Schizophrenia and Depression
Principal Investigator: Jennifer Keller Stanford University
Stanford University
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP